TY - JOUR
T1 - Total cholesterol performance of Abell-Levy-Brodie-Kendall reference measurement procedure
T2 - Certification of Japanese in-vitro diagnostic assay manufacturers through CDC's cholesterol reference method laboratory network
AU - Nakamura, Masakazu
AU - Iso, Hiroyasu
AU - Kitamura, Akihiko
AU - Imano, Hironori
AU - Kiyama, Masahiko
AU - Yokoyama, Shinji
AU - Kayamori, Yuzo
AU - Koyama, Isao
AU - Nishimura, Kunihiro
AU - Nakai, Michikazu
AU - Dasti, Mahnaz
AU - Vesper, Hubert W.
AU - Teramoto, Tamio
AU - Miyamoto, Yoshihiro
N1 - Funding Information:
This work was supported by a Health and Labour Sciences Research Grant, Japan (Comprehensive Research on Lifestyle-Related Diseases Including Cardiovascular Diseases and Diabetes Mellitus) from the Ministry of Health, Labour, and Welfare of Japan . The authors would like to thank Dr. Katsuyuki Nakajima and Dr. Ikunosuke Sakurabayashi for their valuable comments and discussion, and Ms. Yukari Ichikawa for her excellent help in providing the references and manuscript.
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Background: Accurate measurement of total cholesterol (TC) is important for cardiovascular disease risk management. The US Centers for Disease Control and Prevention (CDC) and Cholesterol Reference Method Laboratory Network (CRMLN) perform Abell-Levy-Brodie-Kendall (AK) reference measurement procedure (RMP) for TC as a secondary reference method, and implement Certification Protocol for Manufacturers. Japanese CRMLN laboratory at Osaka performed the AK RMP for 22. years, and conducted TC certification for reagent/calibrator/instrument systems of six Japanese manufacturers every 2. years for 16. years. Osaka TC performance was examined and compared to CDC's reference values. Methods: AK RMP involved sample hydrolysis, cholesterol extraction, and determination of cholesterol levels by spectrophotometry. The Certification Protocol for Manufacturers includes comparison with AK RMP using at least 40 fresh specimens. Demonstration of average bias ≤ 3% and total coefficient of variation ≤ 3% qualified an analytical system for certification. Results: In the AK RMP used in the Osaka CRMLN laboratory, the regression equation for measuring TC was y (Osaka)=1.000x (CDC)+0.032 (n=619, R2=1.000). Six Japanese manufacturers had allowable performance for certification. Conclusions: The AK RMP for TC measurement was accurate, precise, and stable for 22. years. Six Japanese manufacturers were certified for 16. years.
AB - Background: Accurate measurement of total cholesterol (TC) is important for cardiovascular disease risk management. The US Centers for Disease Control and Prevention (CDC) and Cholesterol Reference Method Laboratory Network (CRMLN) perform Abell-Levy-Brodie-Kendall (AK) reference measurement procedure (RMP) for TC as a secondary reference method, and implement Certification Protocol for Manufacturers. Japanese CRMLN laboratory at Osaka performed the AK RMP for 22. years, and conducted TC certification for reagent/calibrator/instrument systems of six Japanese manufacturers every 2. years for 16. years. Osaka TC performance was examined and compared to CDC's reference values. Methods: AK RMP involved sample hydrolysis, cholesterol extraction, and determination of cholesterol levels by spectrophotometry. The Certification Protocol for Manufacturers includes comparison with AK RMP using at least 40 fresh specimens. Demonstration of average bias ≤ 3% and total coefficient of variation ≤ 3% qualified an analytical system for certification. Results: In the AK RMP used in the Osaka CRMLN laboratory, the regression equation for measuring TC was y (Osaka)=1.000x (CDC)+0.032 (n=619, R2=1.000). Six Japanese manufacturers had allowable performance for certification. Conclusions: The AK RMP for TC measurement was accurate, precise, and stable for 22. years. Six Japanese manufacturers were certified for 16. years.
UR - http://www.scopus.com/inward/record.url?scp=84926380068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926380068&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2015.03.026
DO - 10.1016/j.cca.2015.03.026
M3 - Article
C2 - 25818239
AN - SCOPUS:84926380068
SN - 0009-8981
VL - 445
SP - 127
EP - 132
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -